ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2021 and Provide a Corporate Strategic Update

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will announce its financial results for Q1 2021, ending March 31, on May 13, 2021, after market close. A conference call is scheduled for 1:30 p.m. PT/4:30 p.m. ET, allowing investors to discuss results and strategies. ThermoGenesis specializes in automated technologies for cell and gene therapy, including the CAR-TXpress™ platform. The company aims to streamline production in the CAR-T immunotherapy market, enhancing its position in this growing sector.

Positive

• ThermoGenesis is a leader in automated cell processing tools for cell and gene therapy.
• The CAR-TXpress™ platform improves the manufacturing process for CAR-T immunotherapy.

Negative

• None.

RANCHO CORDOVA, Calif., May 6, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 and provide a corporate strategic update on Thursday, May 13, 2021, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.

To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.

A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

View original content:http://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-first-quarter-ended-march-31-2021-and-provide-a-corporate-strategic-update-301285470.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

When will ThermoGenesis Holdings announce its Q1 2021 financial results?

ThermoGenesis will announce its Q1 2021 financial results on May 13, 2021, after market close.

What is the significance of the CAR-TXpress™ platform for ThermoGenesis Holdings?

The CAR-TXpress™ platform is crucial as it streamlines the manufacturing process for CAR-T immunotherapy, enhancing efficiency in cell therapy.

What time is the ThermoGenesis Holdings conference call?

The conference call is scheduled for 1:30 p.m. PT/4:30 p.m. ET on May 13, 2021.

Where can I access the webcast for ThermoGenesis Holdings' conference call?

You can access the live webcast on ThermoGenesis' investor relations page at their website.